



MEDIA RELEASE –FOR IMMEDIATE RELEASE

Immunotec Acquires Assets from Licensee in Mexico and Expands its Seamless Network

VAUDREUIL-DORION, QC, May 3th, 2010 - Immunotec Inc. (TSX Venture Exchange: IMM), a Canadian based company and a leader in the wellness industry (the "Company"), today announced that it has entered into an agreement to acquire certain assets and inventory used by Botanutrific de Mexico SA de CV ("Botanutrific"), a licensee of the Company in Mexico, in connection with the distribution of the Company's products in Mexico.

"We are pleased to expand our seamless network into Mexico, the 6th biggest market* in Multi Level Marketing", said James A. Northrop, President and CEO of Immunotec Inc. "This acquisition confirms our presence in 8 of the top 15 markets worldwide creating new cross border recruitment opportunities with our existing network and by welcoming new Hispanic distributors in a seamless way".

The purchase price includes the payment, on the closing date, of an amount of US \$100,000, as well as a payment for the purchase of inventory held by Botanutrific. The purchase price also includes the payment of an additional amount of US \$100,000 if and when the network sales of a Mexican subsidiary of the Company reach the amount of US \$100,000; a profit-sharing payment equal to 25% of the sum of any positive cumulative excess between the net operating income ratio and the applicable net operating income target, within 30 days of the 3rd anniversary of the closing date; as well as a conditional payment (the "Conditional Payment") of up to US \$500,000, payable in three annual instalments of up to US \$166,667, based on the attainment of certain net operating income targets. The Conditional Payment may, at the Company's option, be effected either in cash or in common shares of the Company (the "Shares"), at a price per share equal to the closing price of the Shares on the TSX-Venture Exchange on the trading day prior to their issuance.

In conjunction with the acquisition of the assets, Botanutrific agrees to terminate its current distributorship agreement, and will enter into an Operating Agreement for the provision of logistical services to the Company's subsidiary in Mexico.

The closing of this transaction is subject to the satisfaction of certain conditions as well as the approval of the TSX-Venture Exchange. The transaction is expected to be finalised within the next month.

*source: WFDSA, Industry News, January 2010

About Immunotec Inc.

Immunotec is a Network Marketing Company involved in the direct selling of scientifically validated natural health products and dietary supplements. The Company offers a lucrative business opportunity to its independent distributors. This business model provides Immunotec's network of people with an opportunity to earn a steady and recurring income, directly based on their level of involvement and performance. Individual distributors build their business by conveying product information and selling product to customers and by building teams of distributors to expand geographic penetration and market coverage to larger populations of customers.



Headquartered with manufacturing facilities near Montreal, Canada, the Company also subcontracts certain distribution logistics and capacity to support its activities in the United States, Europe, Mexico and The Caribbean.

The Company files its consolidated financial statements, its management and discussion analysis report, its press releases and such other required documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

"The TSX Venture does not accept responsibility for the adequacy or accuracy of this release."

For further information: Patrick Montpetit, VP and Chief Financial Officer, (450) 510-4527.